DETECTION OF MEASURABLE RESIDUAL DISEASE IN ADULTS WITH ACUTE LEUKAEMIA

被引：2
作者：
Galtseva, I., V [1 ]
Davydova, Y. O. [1 ]
Parovichnikova, E. N. [1 ]
机构：
[1] Natl Res Ctr Hematol, Moscow 125167, Russia
来源：
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 2020年 / 65卷 / 04期
关键词：
minimal residual disease; measurable residual disease; multicolour flow cytometry; polymerase chain reaction; acute lymphoblastic leukaemia; acute myeloid leukaemia; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; FLOW-CYTOMETRY; CLINICAL-SIGNIFICANCE; STANDARD-RISK; CHILDHOOD; MRD; THERAPY;
D O I：
10.35754/0234-5730-2020-65-4-460-472
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Introduction. Measurable residual disease (MRD) is a residual amount of malignant cells able to invoke relapse after complete haematological remission. Aim. Analysis of the MRD prognostic value in various treatment protocols for acute leukaemia. Main findings. MRD is a good prognostic indicator in lymphoblastic and myeloid leukaemia. Quantification of residual tumour cells is used for patient risk stratification according to the relapse prognosis. Stratification data, including MRD estimates at check points, may impact therapy choice, such as transplantation of allogeneic haematopoietic stem cells. Therefore, MRD estimation in acute leukaemia has become mandatory in clinical trial and research.
引用
收藏
页码：460 / 472
页数：13
相关论文
共 50 条
  • [1] ALL-REZ BFM, 2002, MULT STUD CHILDR REL
  • [2] [Anonymous], 2005, GERMAN MULTICENTER T
  • [3] [Anonymous], 2010, CLIN TRIALS ALEOP BF
  • [4] [Anonymous], 2008, COMBINATION CHEMOTHE
  • [5] Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML
    Anthias, C.
    Dignan, F. L.
    Morilla, R.
    Morilla, A.
    Ethell, M. E.
    Potter, M. N.
    Shaw, B. E.
    [J]. BONE MARROW TRANSPLANTATION, 2014, 49 (05) : 679 - 683
  • [6] Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
    Bassan, Renato
    Spinelli, Orietta
    Oldani, Elena
    Intermesoli, Tamara
    Tosi, Manuela
    Peruta, Barbara
    Rossi, Giuseppe
    Borlenghi, Erika
    Pogliani, Enrico M.
    Terruzzi, Elisabetta
    Fabris, Pietro
    Cassibba, Vincenzo
    Lambertenghi-Deliliers, Giorgio
    Cortelezzi, Agostino
    Bosi, Alberto
    Gianfaldoni, Giacomo
    Ciceri, Fabio
    Bernardi, Massimo
    Gallamini, Andrea
    Mattei, Daniele
    Di Bona, Eros
    Romani, Claudio
    Scattolin, Anna Maria
    Barbui, Tiziano
    Rambaldi, Alessandro
    [J]. BLOOD, 2009, 113 (18) : 4153 - 4162
  • [7] Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow
    Basso, Giuseppe
    Veltroni, Marinella
    Valsecchi, Maria Grazia
    Dworzak, Michael N.
    Ratei, Richard
    Silvestri, Daniela
    Benetello, Alessandra
    Buldini, Barbara
    Maglia, Oscar
    Masera, Giuseppe
    Conter, Valentino
    Arico, Maurizio
    Biondi, Andrea
    Gaipa, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5168 - 5174
  • [8] Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
    Beldjord, Kheira
    Chevret, Sylvie
    Asnafi, Vahid
    Huguet, Francoise
    Boulland, Marie-Laure
    Leguay, Thibaut
    Thomas, Xavier
    Cayuela, Jean-Michel
    Grardel, Nathalie
    Chalandon, Yves
    Boissel, Nicolas
    Schaefer, Beat
    Delabesse, Eric
    Cave, Helene
    Chevallier, Patrice
    Buzyn, Agnes
    Fest, Thierry
    Reman, Oumedaly
    Vernant, Jean-Paul
    Lheritier, Veronique
    Bene, Marie C.
    Lafage, Marina
    Macintyre, Elizabeth
    Ifrah, Norbert
    Dombret, Herve
    [J]. BLOOD, 2014, 123 (24) : 3739 - 3749
  • [9] Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia
    Björklund, E
    Mazur, J
    Söderhäll, S
    Porwit-MacDonald, A
    [J]. LEUKEMIA, 2003, 17 (01) : 138 - 148
  • [10] Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study
    Borowitz, MJ
    Pullen, DJ
    Shuster, JJ
    Viswanatha, D
    Montgomery, K
    Willman, CL
    Camitta, B
    [J]. LEUKEMIA, 2003, 17 (08) : 1566 - 1572
12345